Genovis expands its product portfolio and launches FabALACTICA™
Genovis is expanding its product portfolio and launching yet another unique enzyme for antibody analysis, FabALACTICA™. This enzyme is of particular interest to pharmaceutical companies that develop biological drugs in the growing immunotherapy segment. With the launch of FabALACTICA Genovis will have nine unique enzymes for antibody analysis in the product portfolio, as well as one product for labeling antibodies.Development of new biological drugs in the immunotherapy segment is undergoing strong growth. New types of therapeutic antibodies place new demands on the reagents used for